Press Releases Aridis Pharmaceuticals, Inc.

Equities

ARDS

US0403341045

Delayed OTC Markets Other stock markets 09:48:08 2024-05-07 am EDT			5-day change	1st Jan Change
0.0642 ^USD	0.00%		+7.00%	-8.42%

2023	Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024	Dec. 15	AQ
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update	Nov. 03	AQ
Aridis Pharmaceuticals : Termination of Material Agreement - Form 8-K	23-08-25	PU
Aridis Pharmaceuticals Announces $2 Million Offering	23-08-02	AQ
CapitalGainsReport Penny Stock Bounce List: EPAZ, ARDS, FRTX, GNPX	23-07-24	AQ
Aridis Pharmaceuticals : Accelaration/Increase of Financial Obligation - Form 8-K	23-07-20	PU
Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301	23-07-17	AQ
Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation	23-07-12	AQ
Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)	23-06-20	AQ
ARIDIS PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	23-06-09	AQ
Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update	23-06-08	AQ
Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design	23-05-31	AQ
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q	23-05-25	AQ
ARIDIS PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement (form 8-K)	23-05-09	AQ
ARIDIS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	23-05-01	AQ
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K	23-04-26	AQ
ARIDIS PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	23-04-21	AQ
Aridis Provides Corporate Update	23-03-31	AQ
ARIDIS PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers (form 8-K)	23-03-31	AQ
Aridis Pharmaceuticals : Termination of Material Agreement - Form 8-K	23-03-29	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Aridis Pharmaceuticals, Inc.

Equities

ARDS

US0403341045

Press Releases

Filters